| GENPHARMASEC  Back to All Ratios | 
GENPHARMASEC Last 5 Year Total Debt/Equity History
[Consolidated]
| Mar2024 | Mar2023 | |
|---|---|---|
| Total Debt/Equity(x) | 0.05 | 0.20 | 
What is the latest Total Debt/Equity ratio of GENPHARMASEC ?
| Year | Total Debt/Equity | 
|---|---|
| Mar2024 | 0.05 | 
| Mar2023 | 0.20 | 
How is Total Debt/Equity of GENPHARMASEC Trending?
| Years | Total Debt/Equity | % Change | |
|---|---|---|---|
| Mar2024 | 0.05 | -75.00 | |
| Mar2023 | 0.2 | - | |
Other Financial Ratios of GENPHARMASEC
| Operational & Financial Ratios Earnings Per Share CEPS DPS Book NAV/Share Tax Rate | Margin Ratios Core EBITDA Margin EBIT Margin Pre Tax Margin PAT Margin Cash Profit Margin | Performance Ratios ROA ROE ROCE Asset Turnover Sales/Fixed Asset Working Capital/Sales | Efficiency Ratios Fixed Capital/Sales Receivable days Inventory Days Payable days | Valuation Parameters PER PCE Price/Book Yield EV/Net Sales EV/Core EBITDA EV/EBIT EV/CE M Cap / Sales | Growth Ratios Net Sales Growth Core EBITDA Growth EBIT Growth PAT Growth EPS Growth | Financial Stability Ratios Current Ratio Quick Ratio Interest Cover Total Debt/Mcap | 
Compare Total Debt/Equity ratio of peers of GENPHARMASEC
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GENPHARMASEC | ₹89.1 Cr | -9.6% | -15.3% | -38.8% | Stock Analytics | |
| SUDARSHAN CHEMICAL INDUSTRIES | ₹9,047.2 Cr | -2.5% | -13.7% | 21.2% | Stock Analytics | |
| KIRI INDUSTRIES | ₹3,212.1 Cr | -7.2% | -3.5% | 43.2% | Stock Analytics | |
| VIDHI SPECIALTY FOOD INGREDIENTS | ₹1,673.9 Cr | -0.6% | -5.5% | -25.4% | Stock Analytics | |
| SHREE PUSHKAR CHEMICALS & FERTILISERS | ₹1,292.4 Cr | -3.2% | -10.2% | 69.7% | Stock Analytics | |
| BODAL CHEMICALS | ₹774.3 Cr | 1.1% | -0.6% | -18.8% | Stock Analytics | |
GENPHARMASEC Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year | 
| GENPHARMASEC | -9.6% | -15.3% | -38.8% | 
| SENSEX | -0.3% | 4.5% | 5.7% | 
You may also like the below Video Courses
 
                     
                                     
                                     
                                    